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Abstract: Background:Home-based management of low-risk febrile neutropenia (FN) is safe,
improves quality of life and reduces healthcare expenditure. A formal low-risk
paediatric program has not been implemented in Australia. We aimed to describe the
implementation process and evaluate the clinical impact.
Method:This prospective study incorporated three phases: implementation, intervention
and evaluation. A low-risk FN implementation toolkit wasdeveloped, including a care-
pathway, patient information, home-based assessment and educational resources. The
program had executive-level endorsement, a multidisciplinary committee and a nurse
specialist. Children with cancer and low-risk FN were eligible to be transferred home
with a nurse visiting daily after an overnight period of observation for intravenous
antibiotics. Low-risk patients were identified using a validated decision rule and
suitability for home-based care was determined using disease, chemotherapy and
patient-level criteria. Plan-Do-Study-Act methodology was used to evaluate clinical
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impact and safety.   
Results:Over 18 months, 336 children with FN were screened: 130 (39%) were low-
risk, of which 63 were transferred to home-based care. Compared to pre-
implementation there was a significant reduction in in-hospital median LOS (4.6 to 1.5
days, p<0.001) and 291 in-hospital bed days were saved. Eight (13%) patients needed
readmission and there were no adverse outcomes. A key barrier was timely screening
of all patients and program improvements, including utilising the electronic medical
record for patient identification, are planned.
Conclusion: This program significantly reduces in-hospital LOS for children with low-
risk FN. Ongoing evaluation will inform sustainability, identify areas for improvement
and support national scale up of the program.
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Fabianne is a paediatric infectious diseases specialist with clinical and research
expertise in managing infections in children with cancer.
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Dear Prof. Fred Ashbury, 
 
Submission of an Original Article entitled ‘Home-based care of low-risk febrile neutropenia in 
children – an implementation study in a tertiary paediatric hospital.’ 
 
Home-based management of low-risk febrile neutropenia (FN) in children is recommended in 
international paediatric FN guidelines (Lehrnbecher et al. J Clin Oncol. 2017). Despite this, very few 
centres have adopted this model of care and there are a paucity of studies describing a framework for 
implementation.  
 
Our prospective study describes the process for implementing and evaluating a dedicated paediatric 
low-risk FN program. Over an 18-month period, 63 children with FN were successfully transferred to 
home-based care. Compared to pre-implementation there was a significant reduction in in-hospital 
median length of stay (4.6 to 1.5 days, p<0.001) and 291 in-hospital bed days were saved. A key 
program barriers were identified, including timely risk assessment. 
 
Our study should be published in Supportive Care in Cancer as it is the largest, prospective paediatric 
low-risk FN implementation study conducted to date. We have shown the program is safe and 
significantly impacts length of stay and hospital bed-access. Collectively, our body of research, 
including the implementation study described in this manuscript, has informed a national scaling study. 
This national study has received federal funding which will enable the program to be implemented 
across all eight tertiary paediatric hospitals in Australia.   
 
We believe our study will be of significant interest to your broad academic and clinical. We have 
reported out study according to the Standards for Reporting Implementation Studies (StaRI) guidelines 
as recommended by the EQUATOR network. 
 




Dr Gabrielle Haeusler 
Corresponding author and lead investigator.  
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Background: Home-based management of low-risk febrile neutropenia (FN) is safe, 
improves quality of life and reduces healthcare expenditure. A formal low-risk paediatric 
program has not been implemented in Australia. We aimed to describe the implementation 
process and evaluate the clinical impact. 
 
Method: This prospective study incorporated three phases: implementation, intervention and 
evaluation. A low-risk FN implementation toolkit was developed, including a care-pathway, 
patient information, home-based assessment and educational resources. The program had 
executive-level endorsement, a multidisciplinary committee and a nurse specialist. Children 
with cancer and low-risk FN were eligible to be transferred home with a nurse visiting daily 
after an overnight period of observation for intravenous antibiotics. Low-risk patients were 
identified using a validated decision rule and suitability for home-based care was determined 
using disease, chemotherapy and patient-level criteria. Plan-Do-Study-Act methodology was 
used to evaluate clinical impact and safety.    
 
Results: Over 18 months, 336 children with FN were screened: 130 (39%) were low-risk, of 
which 63 were transferred to home-based care. Compared to pre-implementation there was a 
significant reduction in in-hospital median LOS (4.6 to 1.5 days, p<0.001) and 291 in-
hospital bed days were saved. Eight (13%) patients needed readmission and there were no 
adverse outcomes. A key barrier was timely screening of all patients and program 





































































Conclusion: This program significantly reduces in-hospital LOS for children with low-risk 
FN. Ongoing evaluation will inform sustainability, identify areas for improvement and 
support national scale up of the program. 
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There are increasing data to support home-based management of children with cancer and 
febrile neutropenia (FN) who are at low-risk of infection or medical complications. 
Summarised in two systematic reviews of prospective paediatric FN studies, outpatient and 
oral antibiotic management appears safe, with low rates of treatment failure.[1,2] In keeping 
with these data, international paediatric FN guidelines recommend that centres adopt a 
validated risk stratification program and consider initial or step-down outpatient management 
if the infrastructure is in place to ensure careful monitoring and follow-up.[3,4] However, 
despite the evidence and guideline recommendations, survey data from Australia,[5] the 
United Kingdom,[6] France,[7] and the United States[8] indicate a significant proportion of 
clinicians continue to opt for traditional in-hospital treatment with intravenous antibiotics for 
children with low risk FN.  
The appropriate selection of children with FN at low-risk of infection is fundamental to the 
success of home-based care. To date, as many as 27 attempts have been made to derive a rule 
or set of clinical variables that accurately distinguishes between children at low and high risk 
of infection with varying results in validation.[9,10] This, together with a paucity of studies 
describing an approach to implementation or an evaluation of the clinical, economic and 
quality of life impact of these rules, may, in part, explain the inconsistent uptake of home-
based management of low-risk FN.[11] 
Over the last few years at our tertiary paediatric hospital, a small proportion of patients with 
FN have been transferred for home-based management, but decisions have been ad hoc and 
patients have been transferred late in their course.[12] To address this we conducted 
validation studies to determine the most suitable clinical decision rule to help stratify children 
with cancer and FN into low- and high-risk for infection or adverse event.[13] Beyond 
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validation, we showed that in-hospital length of stay (LOS) is the main contributor to overall 
cost of FN care, and reductions in hospital LOS in patients identified as low risk may 
translate to healthcare savings of up to AUD $2,000 per day.[14] Finally, a randomised 
controlled trial at our centre also found significant carer and patient quality of life benefits in 
favour of home-based care for management of low-risk FN.[15] Based on these and 
international data we piloted a formal low-risk FN program at our hospital. The program was 
adapted from an adult low-risk FN program, successfully implemented at a cancer hospital 
and scaled to other tertiary centres.[16] 
The objective of this study was to describe the process of implementing a paediatric low-risk 
FN program and to prospectively evaluate the clinical impact on LOS and patient safety.  
 
METHODS 
This prospective study incorporated three key phases: implementation, intervention and 
evaluation. It was conducted at a tertiary paediatric hospital with a 26-bed 
haematology/oncology and haematopoietic stem cell transplant (HSCT) unit with the majority 
of patients treated on Children’s Oncology Group chemotherapy protocols. Methodology and 
reporting of results followed the Standards for Reporting Implementation Studies (StaRI) 
statement.[17] The study had ethics approval from The Royal Children’s Hospital Human 
Research Ethics Committee (ethics number 36040). 
 
Implementation. A standardised paediatric low-risk FN implementation toolkit was 
developed and included an evidence-based care pathway, a patient and staff education package, 
and an evaluation protocol (available at https://cancerandinfections.org/kids-low-risk-
toolkit).[18,19] The pathway incorporates a clinical decision rule (CDR), derived by the Swiss 



































































designed to be applied at Day 2 and predicts adverse events using four readily accessible 
clinical variables (intensity of chemotherapy, haemoglobin, white cell count and platelets). 
Adverse event was defined as a serious medical complication (death, complication requiring 
ICU and potentially life-threatening complication as judged by the treating physician) as a 
result of infection, microbiologically defined infection (positive bacterial or fungal culture 
from a normally sterile site and detection of a viral antigen by PCR) or radiologically confirmed 
pneumonia.[20] Additional eligibility or ‘safety-net’ criteria, for early transfer to HITH, 
adapted from a local adult low-risk FN program, were also included in the care pathway (Table 
1).[16] The pathway was endorsed for state-wide use and made available online.[19]  
 
A multidisciplinary working group comprising key stakeholders from oncology, infectious 
diseases, emergency medicine, hospital-in-the-home (HITH), pharmacy, quality and safety and 
the electronic medical record (EMR) team was formed. The group met monthly in the 
preparation phase, quarterly during implementation and were responsible for overseeing all 
aspects of the program. 
 
A dedicated clinical nurse consultant was employed (average 0.25 FTE for 18 months) to assist 
in all phases. Key responsibilities included coordinating steering group meetings, actioning 
items, updating the EMR, staff and patient education, identifying suitable patients, liaison 
between relevant medical departments (HITH, oncology and emergency), ensuring appropriate 
follow up of all patients entered onto the program and clinical data collection. A comprehensive 
education campaign was conducted in the planning phase targeting all medical and nursing 
staff from oncology, infectious diseases, HITH and emergency medicine. Nursing bed 
managers and staff from all medical wards that accept oncology admissions during busy 




































































The hospital EMR (Epic, Epic Systems Corporation) was updated to include a dedicated low-
risk FN program patient pathway. The pathway incorporated the SPOG CDR, HITH eligibility 
criteria (Table 1) and recommended investigations and antibiotics. It enabled a maximum of 
five days of pathology and antibiotic orders before prompting the user to arrange a medical 
review to ensure ongoing HITH suitability.  
 
Intervention. All children (age ≤18 years) with cancer or leukaemia on active treatment and 
diagnosis of fever (≥38°C) and neutropenia (absolute neutrophil count ≤1.0 cells/μL) were 
eligible to be screened for inclusion on the program. Patients who had received a HSCT within 
the preceding 3 months or who developed FN on concurrent treatment antibiotics were 
excluded.  
 
All patients received standard empiric FN investigations and treatment on presentation to the 
emergency department and were admitted to the oncology department. Risk stratification and 
assessment of HITH eligibility was the responsibility of the treating oncology team. Following 
identification of suitable patients with low-risk FN, referral to the HITH unit was made with a 
view to transfer the patient home after a minimum of overnight observation. The patient and 
family received a program information pamphlet, home-assessment chart to record temperature 
and other concerns, and education on when and how to contact the hospital. Once home, the 
patient had a daily clinical review by a HITH nurse, and administration of intravenous 
antibiotics (piperacillin-tazobactam via a 24-hour infuser), pathology samples (full blood 
examination plus others as required) and a clinical assessment. The patient was eligible for 



































































documented infection requiring antibiotics, afebrile >24 hours and evidence of marrow 
recovery including a post-nadir ANC>0.2 cells/mm.3  
 
An urgent in-hospital medical review was arranged for the following indications and 
consideration was given to readmission: recurrent or persistent fever (>48hrs from FN onset) 
or new fever after being afebrile for 24 hours; new signs and symptoms of infection such as 
chills, rigors or shaking; significant decrease in oral intake (<50% baseline) or significantly 
increased fluid losses (vomiting or diarrhoea); positive blood culture result (reported after 
hospital discharge) or other infection requiring in-hospital care.  
 
Evaluation: A prospective cohort design, using Plan-Do-Study-Act (PDSA) methodology, 
was used to evaluate the clinical impact and safety of the program.[21] Detailed patient 
demographic, FN episode and outcome data were collected on all low-risk patients using 
international consensus definitions.[22,23] All deidentified data were entered into an electronic 
database (REDCap).[24] Key clinical impact indicators included: (i) proportion of eligible 
patients entered onto program, (ii) reduction in in-hospital LOS and (iii) total number of bed 
days saved. Safety indicators included (i) number and reason for hospital readmissions and (ii) 
any adverse events (including but not limited to intensive care unit admission or death). This 
quantitative information was used to identify key organisations-, healthcare- and patient-level 
barriers during the ‘study’ phase of the PDSA cycle. 
 
Post implementation clinical data for FN episodes managed on the low-risk FN program were 
compared to pre-implementation data from the Australian PICNICC study and matched 
according to risk status and HITH-eligibility criteria (Table 1).[25] Methodology for the 



































































outcome data were collected on consecutive episodes of FN from eight paediatric tertiary FN 
cancer centres in Australia. There were 304 episodes of outpatient onset FN occurring at our 
hospital from November 2016 to December 2017 of which 122 and 182 episodes were 
classified as low and high risk, respectively. Low-risk episodes that had an infection or adverse 
event known at day 2 (n=11) or who did not fulfil HITH eligibility criteria (n=29) were 
excluded, leaving 82 low-risk pre-implementation episodes for comparison. Similarly, 
following exclusion of episodes that had an infection or adverse event known at day 2 (n=23) 
or who did not fulfil HITH eligibility criteria (n=35) there were 124 high-risk episodes 
available for comparison. 
 
Progress, including key impact and safety measures, were fed back to the Oncology department 
(during multi-disciplinary unit meetings) and the Quality and Safety unit (via written reports) 
on a monthly basis. Additional barriers were identified at the Oncology department meetings 
and proposed solutions discussed. This qualitative information, together with the quantitative 
impact and safety data, were fed back to the steering group and the proposed solutions 
implemented accordingly.  
 
Statistical analysis: Continuous data were presented as median and interquartile range. Mann–
Whitney U test was used to estimate P-values for continuous data and Fisher’s exact test for 






































































Following a 3-month lead-in preparation phase, the program was launched at our hospital on 8 
January 2018.  
 
In the first eighteen months, 336 children with cancer and outpatient onset FN were risk 
assessed, of which 130 (39%) were low-risk and 44 (34%) were transferred to the program to 
complete home-based FN care (Table 2). An additional 19 FN episodes, who were assessed as 
high-risk were also considered appropriate for home-based care by their treating oncologist 
and were transferred to the program. Of the 86 FN episodes assessed as low risk that were not 
transferred home, 20 (23.3%) met HITH eligibility criteria and therefore missed opportunities 
for home-based care (Figure 1).  
 
There was no significant difference in median age, sex and underlying malignancy in the pre 
and post-implementation cohorts (Table 2). Post implementation episodes transferred to home-
based care were significantly more likely to have a fever of unknown cause. For all patients 
entered on the program, the median time from a documented fever greater than 38.0C to HITH 
transfer was 24.0 hours (IQR 12.2-58.8 hours). The median ANC at time of final discharge 
from the program was 0.33 cells/mm3 (IQR 0.15-0.57 cells/mm3).  
 
During treatment at home, there were 36 in-hospital patient medical reviews required for 32 
(50.8%) FN episodes (4 episodes had 2 reviews). Unplanned reasons for in-hospital review 
included: thrombocytopaenia requiring platelet administration (n=7), CVAD complications 
(n=6), positive microbiology results (n=3), gastrostomy site complication (n=1), spurious 
blood result (n=1) and nasogastric tube reinsertion (n=1). Reviews as per protocol included: 
prolonged (>5 days) neutropenia (n=9) and new or prolonged fever (n=8). Reviews resulted in 



































































(IQR 1.2-7.5 days) and median duration of readmission was 7.6 days (IQR 2.6-17.2 days). All 
re-admitted episodes made full recovery and were discharged without complications.  
 
Compared to pre-implementation data (n=82), there was a significant reduction in median in-
hospital LOS for both the low and high-risk FN episodes transferred to the program (4.0 to 1.5 
days, p<0.001) and a total of 291.2 in-hospital bed days were saved. Considered separately, the 
reduction in median in-hospital LOS remained significant for episodes identified as low-risk 
(n=44) but not those identified as high-risk (n=19) (Table 3). However, when compared to pre-
implementation high-risk episodes (n=124), there was a significant reduction in median in-
hospital LOS for the 19 high-risk episodes transferred to the program (4.8 to 1.9 days, p=0.01). 
 
Program barriers. Potential barriers to the program were identified during the ‘study’ phase 
of the PDSA cycle. They were grouped into organisational, clinical staff, patient identification 
and infrastructure. Proposed solutions were determined in collaboration with key stakeholders 
and the program was updated accordingly. Barriers and corresponding solutions, including 
planned changes, are outlined in Table 4.  
 
An important barrier to ensuring all eligible low-risk FN episodes were entered onto the 
program was inconsistent risk-stratification of patients by clinical staff, with 16 low-risk FN 
episodes fulfilling all HITH criteria but not risk stratified (Figure 1). To overcome this, it was 
agreed that the treating team were responsible for risk-scoring all patients with FN and 
assessing suitability for the program. The EMR system has also been utilised to improve timely 
patient identification. A point-of care “best practice” alert (BPA) was developed to appear in 
the EMR if all the following criteria were met: (i) the most recent documented fever since the 



































































< 1.0 cells/μL; (iii) no previous SPOG score had been documented during that admission and; 
(iv) the patient had not been admitted more than 5 days.  The BPA was targeted to the junior 
medical officer or consultant assigned to the treating team responsible for the patient. 
Following implementation, it became apparent that the BPA was not identifying patients with 
profound neutropenia such that their total white cell count was so low (<0.4 cells/μL) that a 
differential count was not performed. The BPA was revised in July and August and impact is 
currently being assessed.    
 
DISCUSSION 
We have shown that implementation of a low-risk FN program, using a structured program 
incorporating a validated CDR, HITH support and clear criteria for readmission is safe, 
feasible and significantly reduced in-hospital LOS. Over an 18-month period, over 290 in-
hospital bed days were saved, likely contributing to substantial healthcare savings.[14] Of the 
patients transferred to the program, 13% required readmission for in-hospital care, in keeping 
with 10% in a recent report of a paediatric low-risk FN program from the USA.[11] A unique 
aspect of our program was the addition of safety-net criteria (outlined in Table 1) to the 
validated CDR. These criteria ensured patients who required in-hospital care despite scoring 
low-risk were not transferred home.  
 
Key components of our low-risk FN program were informed by research conducted locally. 
The CDR selected for use was validated in the target population and modelling provided 
estimates of the number of children likely to benefit from home-based FN management.[13] 
Externally testing the applicability of a CDR prior to implementation is recommended as a 
key component to the validation process.[26] Furthermore, a systematic review found that 



































































based care had significantly lower failure rates of outpatient care compared to studies using 
less stringent tools (7% versus 19%).[1] These factors, together with the multidisciplinary 
approach to implementation and provision of monthly feedback on key performance 
indicators, likely contributed to the success of the program.  
 
Whilst challenging to quantify objectively, the importance of a dedicated clinical nurse 
consultant supporting all three phases of the program cannot be overstated. The nurse played 
a crucial role in staff and patient education, patient identification, program evaluation as well 
as liaison between families on the program and relevant hospital staff. In a systematic review 
of nurse-led ambulatory programs, clinical outcomes were largely equivalent to physician-led 
programs, with some areas of health-related quality of life better in the nurse-led models.[27] 
While high quality economic evaluations are lacking, some studies have shown lower costs in 
nurse-led programs, largely driven by fewer hospital readmissions and shorter LOS.[27]  
 
Comprehensive evaluation of the program has identified key areas for improvement, in 
particular ensuring all patients are risk-assessed to avoid missed opportunities for home-
based care. Automated identification of all patients with FN and alerting relevant clinicians 
via the EMR is a potential way to improve case ascertainment. To date, no studies have 
explored the impact of this approach in the management of low-risk FN. Randomised trials of 
automated monitoring and alerts in adult patients with sepsis show mixed results ranging 
from no effect [28] to a significant reduction in LOS and mortality.[29] A key difference 
between these studies was the lack of accompanying management recommendations in the 
former study, suggesting that these alerts may not work in isolation and would likely benefit 




































































An unintended consequence of the program is the longer total LOS (ie. inclusive of both in-
hospital and HITH LOS) in the post-implementation group compared to the pre-
implementation group. This may, in part, be explained by clinicians taking a more 
conservative approach to patients being managed at home. While the median ANC at 
discharge from the program was 0.33 cells/mm3, one quarter of patients continued to receive 
antibiotics until ANC was greater than 0.6 cells/mm.3 Targeted education that earlier 
discharge and cessation of antibiotics is safe, together with introduction of nurse-led 
discharge criteria are potential solutions being implemented. Options for oral antibiotics have 
also been included in the pathway and education regarding the safety and efficacy of this 
approach is ongoing.[1,2] 
 
A key strength of our study is in the use of prospectively collected pre- and post- 
implementation data to assess the clinical impact of our program. We have also followed 
international consensus guidelines for the reporting of implementation studies.[30,31] 
We are currently extending our work to investigate the economic and quality of life impacts 
of this low-risk FN program, adopting similar methodology to a study of an adult low-risk 
FN program that showed significant cost savings.[16,32] In a baseline economic analysis we 
identified that the mean cost of standard, in-hospital management of paediatric low-risk FN 
was $2,200 AUD per day[32]. As the mean costs incurred for home based-care of FN in 
Australia is AUD $828, the cost benefit of our program is likely to be substantial.  
 
A structured low-risk FN program incorporating risk assessment, regular observation and 
appropriate safeguards, has enabled children with cancer at our institution to benefit from 
home-based FN care. By saving 290 in-hospital bed days in 18 months, we have also 



































































chemotherapy and reduced the burden on other speciality wards. This program in currently 
being scaled nationally, thereby increasing the clinical, economic and quality of life impact of 
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High risk disease group High risk diseas status Expected duration
neutropenia >7d
Treating team choice
Missed opportunities Appropriate in-hospital care
Figure 1
Table 1: Eligibility criteria for early transfer to hospital-in-the-home (must be YES to all to 
proceed): 
Criteria Eligible Not 
eligible 
Disease status. Leukaemia/lymphoma in remission (as per last BMA) 
or solid tumour stable/responding (as per oncologist) 
 Yes  No 
Disease group. Not any of: ALL induction, infant ALL, AML, post 
HSCT, congenital immunodeficiency, aplastic anaemia 
 Yes  No 
Expected duration of neutropenia < 7 days   Yes  No 
No confirmed focus of infection requiring inpatient carea  Yes  No 
No medical complication requiring inpatient careb  Yes  No 
No severe sepsis at FN presentationc  Yes  No 
No active infection with multi-drug resistant bacteria   Yes  No 
Availability of a 24 hour caregiver  Yes  No 
Good education of patient and carer on reportable symptoms  Yes  No 
Availability of a telephone (with credit)   Yes  No 
Availability of 24 hour phone advice/emergency department review 
from treating hospital 
 Yes  No 
Within 1-hour of an emergency department or treating hospital  Yes  No 
Treating team preference  Yes  No 
No previous history of non-compliance with medical care  Yes  No 
BMA is bone marrow aspirate; ALL, acute lymphoblastic leukaemia; AML acute myeloid 
leukaemia; HSCT, haematopoetic stem cell transplant; FN, febrile neutropenia 
Tables
aincluding, but not limited to, central venous catheter site infection, cellulitis, perianal cellulitis 
or pain, pneumonia, colitis.  
bincluding, but not limited to, pain requiring intravenous analgesia, poor oral intake or 
excessive loss requiring intravenous hydration; respiratory distress or oxygen requirement; 
pulmonary infiltrates on CXR. 
csevere sepsis includes any of (i) altered conscious state, (ii) inotrope requirement, (iii) fluid 








Table 2. Demographic and outcome data of pre-implementation FN episodes[25] and post-






Median age, years 
(IQR) 
5.5 (3.3-8.3) 7.0 (2.7-9.4)  0.57 
Female, n (%) 42 (51%) 33 (52.4) >0.99 
Haematological 


























IQR is interquartile range; MDI is microbiologically defined infection; CDI is clinically 
defined infection; arestricted to outpatient onset low risk FN who fulfilled HITH criteria and 





















Post implementation P value 
(Column 
A vs C) 
Low risk 















hospital LOS, d 
(IQR) 
4.0 (2.4-6.8) 5.6 (2.7-
10.8) 
1.3 (1.0-2.8) 1.9 (0.9-10.6) 0.001* 
 
Median HITH 
LOS, d (IQR) 
NA 0 3.6 (2.1-5.0) 4.5 (2.9-6.0) - 
Median total 
LOS, d (IQR) 
4.0 (2.4-6.8) 5.6 (2.7-
10.8) 
5.7 (3.9-7.2) 8.3 (4.1-15.8) 0.01b 
Readmissions, n 
(%) 
NA NA 6 (13.6) 2 (10.5) - 
ICU admission 0 2 (2.3) 0 0 - 
Total bed days 
saved, n 
0 0 184.9 106.3 - 










Sustainability solutions  
Organisational  
Education and 
training of all 
staff 
 Standardised education included in all new medical and nursing  
orientation package 
 Update to online paediatric FN learning module to include 




 Formal economic and QOL analysis to inform business case for 




 All new medical and nursing staff are required to complete 
orientation package containing information about low-risk FN 
program 
 Program education delivered by medical and nursing education 
leads within the oncology unit 
Clinician 
engagement 
 Regular (monthly) email communiques to update clinical staff on 
program progress including patient recruitment, LOS reductions, 
bed-days saved and readmissions 




 Clinical role (oncology registrar/fellow), rather than individual 
person, responsible for risk assessment of all patients with FN 




 Recalibrate SPOG clinical decision rule following analysis of 
prospective Australian PICNICC study data 
Prolonged HITH 
LOS 
 Nurse led HITH discharge criteria 




 Include recommendations for oral antibiotics (amoxicillin-





 EMR systems to be updated to assist in automated collection of key 
outcomes including LOS, number screened, number transferred 
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